DDX3X is altered in 10.26% of medulloblastoma patients [3].

DDX3X is an inclusion criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

DDX3X is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

DDX3X is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

DDX3X is altered in 23.08% of desmoplastic/nodular medulloblastoma patients [3].

DDX3X is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is altered in 16.67% of large cell/anaplastic medulloblastoma patients [3].

DDX3X is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is altered in 7.41% of central nervous system embryonal neoplasm patients [3].

DDX3X is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

DDX3X is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain DDX3X status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

DDX3X is altered in 0.55% of glioblastoma patients [3].

DDX3X is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is altered in 0.37% of malignant glioma patients [3].

DDX3X is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is altered in 0.34% of diffuse glioma patients [3].

DDX3X is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

DDX3X is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].